10 Best High Quality Low Ev Ebit Stocks for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The current market landscape is marked by heightened volatility and sector rotation, with investors seeking resilient companies that combine strong fundamentals and attractive valuations. Our selection methodology leverages ValueSense’s proprietary intrinsic value models, quality ratings, and sector diversification to identify stocks with robust financial health, growth potential, and undervaluation signals. Each pick is screened for high return on invested capital (ROIC), reasonable debt levels, and positive free cash flow margins, ensuring a balanced, data-driven approach[1][2].
Featured Stock Analysis
American Express Company (AXP)
| Metric | Value |
|---|---|
| Market Cap | $251.8B |
| Quality Rating | 7.3 |
| Intrinsic Value | $322.8 |
| 1Y Return | 34.7% |
| Revenue | $78.6B |
| Free Cash Flow | $27.0B |
| Revenue Growth | 8.1% |
| FCF margin | 34.4% |
| Gross margin | 83.0% |
| ROIC | 48.4% |
| Total Debt to Equity | 4.5% |
Investment Thesis
American Express stands out as a high-quality financial services provider with a market cap of $251.8B and a ValueSense quality rating of 7.3. The company’s intrinsic value is calculated at $322.8, suggesting notable upside from current levels. Over the past year, AXP delivered a strong 34.7% return, supported by $78.6B in revenue and $27.0B in free cash flow. Its 8.1% revenue growth and exceptional 48.4% ROIC highlight operational efficiency and capital discipline.
Key Catalysts
- Expansion in premium card offerings and global merchant network
- Consistent double-digit free cash flow margins 34.4%
- High gross margin 83.0% supports profitability
- Strategic investments in digital payments and fintech partnerships
Risk Factors
- Elevated total debt to equity 4.5% may limit flexibility
- Exposure to cyclical consumer spending trends
- Competitive pressures from fintech disruptors
Novo Nordisk A/S (NVO)
| Metric | Value |
|---|---|
| Market Cap | $219.9B |
| Quality Rating | 6.5 |
| Intrinsic Value | $77.4 |
| 1Y Return | -55.8% |
| Revenue | DKK 311.9B |
| Free Cash Flow | DKK 62.0B |
| Revenue Growth | 20.9% |
| FCF margin | 19.9% |
| Gross margin | 83.9% |
| ROIC | 29.7% |
| Total Debt to Equity | 59.1% |
Investment Thesis
Novo Nordisk, a global leader in diabetes and obesity care, commands a $219.9B market cap and a ValueSense quality rating of 6.5. Despite a challenging year (-55.8% 1Y return), the company’s intrinsic value of $77.4 and robust revenue growth 20.9% signal long-term potential. With DKK 311.9B in revenue and DKK 62.0B in free cash flow, Novo Nordisk maintains industry-leading gross margins 83.9% and a healthy 29.7% ROIC.
Key Catalysts
- Strong pipeline of GLP-1 and obesity therapies
- Expansion into emerging markets
- High gross margin supports reinvestment in R&D
- Strategic acquisitions and partnerships
Risk Factors
- High total debt to equity 59.1%
- Currency risk due to international operations
- Regulatory uncertainties in healthcare pricing
Merck & Co., Inc. (MRK)
| Metric | Value |
|---|---|
| Market Cap | $215.2B |
| Quality Rating | 7.1 |
| Intrinsic Value | $107.2 |
| 1Y Return | -15.3% |
| Revenue | $63.6B |
| Free Cash Flow | $14.7B |
| Revenue Growth | 1.8% |
| FCF margin | 23.1% |
| Gross margin | 81.2% |
| ROIC | 25.7% |
| Total Debt to Equity | 72.2% |
Investment Thesis
Merck is a diversified pharmaceutical giant with a $215.2B market cap and a ValueSense quality rating of 7.1. The company’s intrinsic value is $107.2, and while its 1Y return is -15.3%, Merck’s $63.6B revenue and $14.7B free cash flow reflect stable operations. Its 81.2% gross margin and 25.7% ROIC underscore efficiency, with a focus on oncology and vaccine innovation.
Key Catalysts
- Leading oncology portfolio (Keytruda)
- Expansion in vaccine and animal health segments
- Strong free cash flow margin 23.1%
- Ongoing R&D investments
Risk Factors
- High total debt to equity 72.2%
- Patent expirations and generic competition
- Regulatory and pricing pressures
PDD Holdings Inc. (PDD)
| Metric | Value |
|---|---|
| Market Cap | $188.4B |
| Quality Rating | 6.8 |
| Intrinsic Value | $397.9 |
| 1Y Return | 11.8% |
| Revenue | CN¥409.6B |
| Free Cash Flow | CN¥94.2B |
| Revenue Growth | 19.9% |
| FCF margin | 23.0% |
| Gross margin | 57.4% |
| ROIC | (90.5%) |
| Total Debt to Equity | 3.0% |
Investment Thesis
PDD Holdings, a fast-growing e-commerce platform, boasts a $188.4B market cap and a ValueSense quality rating of 6.8. Its intrinsic value is $397.9, with an 11.8% 1Y return. The company generated CN¥409.6B in revenue and CN¥94.2B in free cash flow, with impressive 19.9% revenue growth. PDD’s asset-light model and aggressive market expansion drive its growth trajectory.
Key Catalysts
- Rapid user growth in China and international markets
- High free cash flow margin 23.0%
- Strategic investments in logistics and technology
- Expansion into new product categories
Risk Factors
- Negative ROIC -90.5% signals capital allocation concerns
- Regulatory risks in China
- Competitive pressures from established e-commerce giants
Accenture plc (ACN)
| Metric | Value |
|---|---|
| Market Cap | $155.7B |
| Quality Rating | 6.8 |
| Intrinsic Value | $271.1 |
| 1Y Return | -27.2% |
| Revenue | $69.7B |
| Free Cash Flow | $10.9B |
| Revenue Growth | 7.4% |
| FCF margin | 15.6% |
| Gross margin | 31.9% |
| ROIC | 19.4% |
| Total Debt to Equity | 25.4% |
Investment Thesis
Accenture is a global consulting and technology services leader with a $155.7B market cap and a ValueSense quality rating of 6.8. The company’s intrinsic value is $271.1, but its 1Y return is -27.2%. Accenture’s $69.7B revenue and $10.9B free cash flow are supported by steady 7.4% revenue growth. Its diversified client base and digital transformation expertise position it for long-term resilience.
Key Catalysts
- Leadership in cloud, AI, and digital transformation
- Expanding global footprint
- Strong client retention and recurring revenue streams
- Strategic acquisitions
Risk Factors
- Moderate total debt to equity 25.4%
- Exposure to macroeconomic cycles
- Competitive consulting landscape
Unilever PLC (UL)
| Metric | Value |
|---|---|
| Market Cap | $148.9B |
| Quality Rating | 7.3 |
| Intrinsic Value | $95.9 |
| 1Y Return | 0.4% |
| Revenue | €120.1B |
| Free Cash Flow | €14.5B |
| Revenue Growth | 2.5% |
| FCF margin | 12.1% |
| Gross margin | 71.3% |
| ROIC | 32.1% |
| Total Debt to Equity | 160.7% |
Investment Thesis
Unilever, a global consumer goods powerhouse, has a $148.9B market cap and a ValueSense quality rating of 7.3. Its intrinsic value is $95.9, with a modest 0.4% 1Y return. Unilever’s €120.1B revenue and €14.5B free cash flow reflect stable operations, with a 2.5% revenue growth rate. The company’s 71.3% gross margin and 32.1% ROIC highlight operational strength.
Key Catalysts
- Diverse product portfolio across food, personal care, and home care
- Strong brand equity and global reach
- Focus on sustainability and innovation
- High free cash flow margin 12.1%
Risk Factors
- Elevated total debt to equity 160.7%
- Exposure to commodity price fluctuations
- Intense competition in consumer staples
Anheuser-Busch InBev SA/NV (BUD)
| Metric | Value |
|---|---|
| Market Cap | $121.4B |
| Quality Rating | 7.1 |
| Intrinsic Value | $71.9 |
| 1Y Return | 2.6% |
| Revenue | $73.5B |
| Free Cash Flow | $11.7B |
| Revenue Growth | 22.7% |
| FCF margin | 15.9% |
| Gross margin | 55.7% |
| ROIC | 17.3% |
| Total Debt to Equity | 82.7% |
Investment Thesis
Anheuser-Busch InBev, a leading global brewer, holds a $121.4B market cap and a ValueSense quality rating of 7.1. Its intrinsic value is $71.9, with a 2.6% 1Y return. The company’s $73.5B revenue and $11.7B free cash flow are driven by 22.7% revenue growth and a 15.9% free cash flow margin. AB InBev’s scale and brand portfolio provide competitive advantages.
Key Catalysts
- Strong global distribution network
- Expansion in premium and craft beer segments
- Cost optimization initiatives
- High gross margin 55.7%
Risk Factors
- High total debt to equity 82.7%
- Regulatory risks in alcohol markets
- Currency and commodity price volatility
British American Tobacco p.l.c. (BTI)
| Metric | Value |
|---|---|
| Market Cap | $113.4B |
| Quality Rating | 7.4 |
| Intrinsic Value | $139.0 |
| 1Y Return | 49.3% |
| Revenue | £37.9B |
| Free Cash Flow | £11.7B |
| Revenue Growth | (30.9%) |
| FCF margin | 30.9% |
| Gross margin | 83.1% |
| ROIC | 14.3% |
| Total Debt to Equity | 74.9% |
Investment Thesis
British American Tobacco, a global tobacco leader, features a $113.4B market cap and a ValueSense quality rating of 7.4. Its intrinsic value is $139.0, with a strong 49.3% 1Y return. BTI’s £37.9B revenue and £11.7B free cash flow are offset by a -30.9% revenue growth rate, but its 83.1% gross margin and 30.9% free cash flow margin support profitability.
Key Catalysts
- Expansion in reduced-risk products (vaping, heated tobacco)
- High free cash flow generation
- Strong brand portfolio
- Cost management initiatives
Risk Factors
- High total debt to equity 74.9%
- Regulatory and litigation risks
- Declining traditional tobacco volumes
Altria Group, Inc. (MO)
| Metric | Value |
|---|---|
| Market Cap | $94.9B |
| Quality Rating | 7.1 |
| Intrinsic Value | $96.1 |
| 1Y Return | 5.5% |
| Revenue | $20.2B |
| Free Cash Flow | $11.6B |
| Revenue Growth | (1.0%) |
| FCF margin | 57.4% |
| Gross margin | 72.0% |
| ROIC | 90.7% |
| Total Debt to Equity | (68.3%) |
Investment Thesis
Altria Group, a major U.S. tobacco company, has a $94.9B market cap and a ValueSense quality rating of 7.1. Its intrinsic value is $96.1, with a 5.5% 1Y return. Altria’s $20.2B revenue and $11.6B free cash flow are supported by a 57.4% free cash flow margin and a remarkable 90.7% ROIC, indicating efficient capital use.
Key Catalysts
- Strong cash flow supports dividends and buybacks
- Expansion into reduced-risk products
- Strategic investments in cannabis and vaping
- High gross margin 72.0%
Risk Factors
- Negative total debt to equity -68.3%
- Regulatory and litigation risks
- Declining cigarette volumes
Bristol-Myers Squibb Company (BMY)
| Metric | Value |
|---|---|
| Market Cap | $93.8B |
| Quality Rating | 6.4 |
| Intrinsic Value | $90.2 |
| 1Y Return | -16.5% |
| Revenue | $48.0B |
| Free Cash Flow | $15.3B |
| Revenue Growth | 1.3% |
| FCF margin | 31.9% |
| Gross margin | 66.1% |
| ROIC | 15.0% |
| Total Debt to Equity | 263.3% |
Investment Thesis
Bristol-Myers Squibb, a leading pharmaceutical company, has a $93.8B market cap and a ValueSense quality rating of 6.4. Its intrinsic value is $90.2, with a -16.5% 1Y return. BMY’s $48.0B revenue and $15.3B free cash flow are supported by a 31.9% free cash flow margin and a 66.1% gross margin, with a focus on oncology and immunology.
Key Catalysts
- Strong pipeline in oncology and immunology
- High free cash flow generation
- Strategic acquisitions and partnerships
- Cost optimization initiatives
Risk Factors
- Very high total debt to equity 263.3%
- Patent expirations and competition
- Regulatory and pricing pressures
Portfolio Diversification Insights
This watchlist spans financials, healthcare, consumer staples, technology, and e-commerce, providing sector diversification to mitigate risk. Healthcare stocks (NVO, MRK, BMY) offer defensive growth, while consumer staples (UL, BUD, BTI, MO) provide stability and cash flow. Technology and consulting (ACN, PDD) add growth and innovation exposure. The portfolio balances high ROIC and free cash flow margins across cyclical and non-cyclical sectors, reducing single-sector vulnerability.
Market Timing & Entry Strategies
Consider phased entry strategies such as dollar-cost averaging to manage volatility and avoid market timing risks. Monitor earnings releases and macroeconomic indicators for optimal entry points. ValueSense’s intrinsic value ratings can help identify periods of undervaluation, while sector rotation trends may signal opportunities for rebalancing. Use stop-loss and position sizing to manage downside risk.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were chosen using ValueSense’s proprietary screening tools, focusing on intrinsic value, quality ratings, ROIC, and sector diversification. Only companies with strong fundamentals and undervaluation signals were included[1][2].
Q2: What's the best stock from this list?
Each stock offers unique strengths; for example, American Express (AXP) and British American Tobacco (BTI) have high quality ratings and strong recent returns. The “best” depends on individual investment goals and risk tolerance.
Q3: Should I buy all these stocks or diversify?
Diversification across sectors (financials, healthcare, consumer staples, technology) helps reduce risk. Investors may consider allocating across several picks rather than concentrating in one area.
Q4: What are the biggest risks with these picks?
Risks include high debt levels, regulatory changes, competitive pressures, and sector-specific challenges. Each stock’s risk profile is detailed in its analysis section above.
Q5: When is the best time to invest in these stocks?
Optimal timing depends on market conditions, earnings cycles, and valuation signals. Dollar-cost averaging and monitoring ValueSense’s intrinsic value ratings can help identify attractive entry points.